Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

statements that can be identified by terminology such as "potential," "to present," "to show," "to demonstrate," "can," "will," "to explore," "pipeline," or similar expressions, or by express or implied discussions regarding potential new indications or labeling, or potential marketing approvals for the products described in this release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any of the products or additional indications or labeling described in this release will be submitted for approval or approved for sale in any market. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove inco
'/>"/>
SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... Aug. 29, 2014  A Boston Scientific Corporation ... on stent removability and preliminary long term stricture ... in the August issue of the peer-reviewed journal, ... is being conducted in 11 countries and ... self-expanding metal stents (FCSEMS) after extended indwell (i.e., ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides many kinds ... employee internet monitoring products ( http://www.os-monitor.com ). Furthermore, the ... 10% off, on these useful items. , True ... different kinds of high end monitoring programs on its ... of all sizes. With its high end programs, the ...
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an interview ... role as a kicking coach, his kicking business, and on ... retired NFL kicker Michael Husted author of HustedKicking.com. , "Anthony ... one of the top pro free agent kickers out there,” ... at our 2014 Pro Camp and I was impressed with ...
(Date:9/2/2014)... simple awareness campaign in general practice identifies new cases ... ESC Congress today by Professor Jean-Marc Davy from France. ... most common cardiac arrhythmia. It multiplies the risk of ... stroke risk by five-fold. Similarly, AF is responsible for ... is often overlooked and diagnosed too late. In 20% ...
(Date:9/2/2014)... 2 September 2014: Health structures explain nearly 20% ... to the results of a joint ESC-OECD study ... Maggioni. Clinical variables explained more than 80% of ... unique evaluation which combines clinical data and health ... fuller picture of the reasons some patients with ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Developers and ... announced a new ProIntro Lesson from Pixel Film Studios. ... easy and fresh-looking titles,” said Christina Austin, CEO of ... armature, ProIntro is a definite game changer.” , Learn ... ProIntro Lesson from Pixel Film Studios. ProIntro is a ...
Breaking Medicine News(10 mins):Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3
... Healthcare announces the following Webcast:, What: HCA Healthcare ... Where: http://www.videonewswire.com/event.asp?id=55052 , How: ... the, address ... +1-615 344 2688, , ...
... STERIS Corporation (NYSE:, STE ) today announced ... 31, 2008. Fiscal 2009 third quarter revenues increased ... third quarter of fiscal 2008,driven by 4% growth in ... income was $28.6 million, or $0.48 per diluted share, ...
... Genetics, Inc. (NYSE Alternext US: ILI) today announced that the ... LLC (the "Exchange") that outlines the Company,s strategy to regain ... expects the Exchange to formally respond to the submitted plan ... may be able to continue its listing up to June ...
... New Couple,s Guide Provides Blueprint for Renewing RelationshipsNEW YORK, ... disappoint. But for relationships on the rocks, nothing says, ... a breakthrough guide, seasoned couples therapist and educator Marty ... with the differences that arise in any relationship. "We,ve ...
... custom fabrication offerings to include products for use in hospitals. ... work stations, surgical tools, and carts for use in the medical environment. ... ... work as a custom sheet metal fabrication house over 30 years ago. ...
... information portal with the recent addition of several new articles detailing ... drug has been linked to bone fracture, osteoporosis and heart failure ... ... 2009 -- LegalView.info, the most comprehensive legal site available on the ...
Cached Medicine News:Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 2Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 3Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 4Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 5Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 6Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 7Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 8Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 9Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 10Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 11Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 12Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 13Health News:STERIS Corporation Announces Fiscal 2009 Third Quarter Results 14Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:Breakthrough Rx for Relationships Offers Hope 2Health News:Midbrook Now Offers Custom Metal Fabrication for Hospitals 2Health News:LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects 2Health News:LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects 3
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
... 1700 was developed to address hematology ... Ease of use, low maintenance, closed-tube ... reliability are features expected in the ... made fast access to results, sophisticated ...
Inquire...
Medicine Products: